The Gold Rush for Weight Loss Medications is Gaining Momentum

Lilly's quarterly results on October 30, 2025, combined with Novo Nordisk's (i) takeover bid for Metsera, confirm that the $72 billion market for obesity medications is one of the hottest segments in the pharmaceutical industry. The New Pharma Gold Rush On October 30, 2025, Eli Lilly reported a quarterly revenue increase thanks to its medications, while Novo Nordisk, the other major player in the market, took the unusual step of making a billion-dollar bid for a weight loss startup that had previously agreed to sell to Pfizer. Overall, these...